Target Corp (NYSE:TGT) is set to release third-quarter earnings on November 19, with analysts warning of potential headwinds in sales and margins amid slowing digital growth and broader retail pressures. Bank of America projects the retailer will report adjusted earnings of $1.67 per share and a 1% decline in comparable-store sales, slightly below consensus estimates of $1.72 per share and a 1.8% drop in comps.

Norwegian Cruise shares slide 28% in three months as pricing dilution, higher leverage and heavier Caribbean exposure pressure sentiment.

FDX's cost cuts, stronger leverage and upbeat fiscal second-quarter outlook contrast with UPS' struggles, shaping the parcel giants' diverging prospects.

Canada's industry minister aims to deliver a decision next month on whether Anglo American can proceed with its takeover of Teck Resources, but warned that the British miner's pledges to date aren't enough.

Meme stocks have created a world of volatility, and Opendoor Technologies ( NASDAQ:OPEN ) is the latest darling of the stock chatrooms that has captured the attention of traders, leading to a dramatic turnaround in 2025.

Futu Holdings Limited delivered strong Q3 results with 86% revenue growth and significant increases in funded accounts and client assets. FUTU's expansion in Hong Kong, Malaysia, and the U.S., plus robust crypto trading volumes, fueled recent growth despite broader market volatility. Risks include heavy reliance on crypto trading momentum and potential spillover from declining tech stocks and cryptocurrencies like Bitcoin and Ethereum.

The Syrian Petroleum Company, U.S.-based ConocoPhillips and Novaterra have signed a memorandum of understanding to expand cooperation in the natural gas sector, Syria's energy ministry said on Tuesday.

HP posts a mixed Q4 as earnings miss but revenues beat estimates, with strong offshore growth offset by international losses and one-time charges.

Nvidia has been resting on an inflection point in recent session.

- EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is now the first and only bispecific antibody combination therapy available for patients with relapsed or refractory follicular lymphoma after at least one line of systemic therapy - In the Phase 3 EPCORE® FL-1 trial, EPKINLY + R2 demonstrated significantly superior progression-free survival and overall response rates compared to standard of care R2 with approximately 3 out of 4 patients achieving a complete response - Approval marks third indication for EPKINLY and first-ever FDA approval for a bispecific combination therapy in lymphoma NORTH CHICAGO, Ill. , Nov. 18, 2025 /PRNewswire/ -- …

Navitas Semiconductor Corporation (NVTS) is pivoting from mobile chargers to AI data centers with a possible future outlook to tap into energy infrastructure, and industrial electrification, targeting high-growth sectors. NVTS faces deteriorating fundamentals, with a 53% YoY revenue decline and high valuation multiples, making current stock levels speculative despite future growth projections. Execution risk is significant as NVTS transitions, requiring new customer relationships and facing strong competition from established chipmakers with integrated manufacturing.

AP reports stronger third-quarter 2025 results as ALP hits record EBITDA and facility exits reshape earnings potential.

Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.

HIMS faces rising regulatory strain, margin pressure and competition despite strong revenue momentum.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Dick's (DKS) have what it takes?

As Buffett prepares to step back as CEO of Berkshire Hathaway, the company is making moves few would expect from the Oracle of Omaha.

Spotify Technology SA (NYSE:SPOT)'s announcement of a new Platinum subscription tier has been welcomed by Jefferies analysts with cautious optimism. Spotify on Monday unveiled its Platinum tier in five test markets (India, Indonesia, South Africa, UAE, and Saudi Arabia), marking a shift in the company's subscription strategy.

Netflix Inc.'s (NASDAQ: NFLX) stock slump has intensified amid mounting investor concerns about media dealmaking, rising competition, and questions over the company's next phase of growth

Merck & Co. Inc. (NYSE: MRK) on Tuesday released topline results from the Phase 2 CADENCE study of Winrevair (sotatercept-csrk) in adults for combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF).

BRK.B reshapes its portfolio, boosting Alphabet holdings while trimming Apple as part of a broader bid to reduce concentration risk.